Cantargia (OMX: CANTA)

Last close As at 21/02/2025

SEK1.52

−0.04 (−2.56%)

Market capitalisation

SEK389m

Cantargia is a clinical-stage biotech company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Latest Insights

View More

Healthcare | Comment

Cantargia (OMX: CANTA) reports positive CAN10 results

Healthcare | Comment

Cantargia (OMX: CANTA) publishes robust Phase II PDAC data

Healthcare | Flash note

Cantargia — Encouraging data for nadunolimab in CANFOUR

Healthcare | Flash note

Cantargia — First patient treated in Phase II part of TRIFOUR

Sector

Healthcare

Equity Analyst

Key Management

  • Goran Forsberg

    CEO

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free